They further underscore Gal-9 monotherapy or combined treatment regimens targeting additional Gal-9 axis components, TIM-3, CEACAM1, and/or PD-1, and other pathways as potentially synergistic approaches to cancer therapy. The gene discussed is PDCD1; the disease is cancer.